drugset / Trial / NCT02020122

Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles

NCT02020122

Completed 5 enrolled Rambam Health Care Campus
RandomizedParallel-groupDouble-blindPrevention

Summary

To utilize the plasticity of the central pain pathways in order to (i) shift individuals with a pro-nociceptive pain modulation profile towards an anti-nociceptive one, and (ii) assess its relevance in minimizing pain-derived morbidity.

Timeline

Start
2014-01
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg
Comparator Pregabalin Small molecule 150 mg

Indications

No indication recorded.